Korio

Korio, Inc. develops Randomization and Trial Supply Management (RTSM), also referred to as IRT, software for clinical trials. The platform is designed to support studies across the full lifecycle, from rapid study startup through kickoff, protocol amendments and study closeout. Core capabilities described by the company include a configurable system that absorbs protocol changes, reusable validated components, automated testing, a streamlined configuration model, and role-based dashboards giving real-time visibility into subject activity, investigational product supply and system health, with proactive monitoring to flag issues.

The company positions itself as focused exclusively on RTSM rather than offering a broader all-in-one eClinical suite. Alongside the software, Korio provides continuity of staffing: experienced RTSM project managers remain with a study from kickoff to closeout and have direct access to the platform's configuration tools so changes can be implemented without separate engineering work. Sponsors are also given direct access to the founder-led leadership team. Korio has published case studies covering a personalized-medicine oncology trial taken over mid-study, a rare disease biotech replacing manual processes, and a Phase I trial migrating from spreadsheets to RTSM.

Founding story

Korio was co-founded by Ryan Keane (Founder and CEO) and Chuck Harris (Founder and COO), both of whom previously worked at clinical trial technology provider Endpoint Clinical. Keane spent roughly 15 years in life sciences, beginning as a biostatistician at CRO Pacific Data Designs after an MS in Biostatistics, then ten years at Endpoint Clinical where he rose from business development to Vice President, Business Development and ultimately Chief Commercial Officer. Harris began in regulatory work at the FDA in Boston, moved through consumer technology roles at Excite and Intuit, and then spent two decades in clinical trial technology leadership in San Francisco, most recently as CEO of Endpoint Clinical. He describes co-founding Korio as an opportunity to build an evolved clinical trials platform from a blank canvas. The name Korio is derived from the word "chorus."

Business model

Korio sells RTSM/IRT software to clinical trial sponsors, bundled with expert client services including dedicated project managers who remain assigned to a study for its duration and who configure the system directly.

Traction

The company reported a surge in customer adoption over the year preceding its September 2024 Series A, and publishes case studies including a mid-trial RTSM takeover for a personalized medicine oncology study, a rare disease biotech and a live Phase I trial.

Latest developments

In September 2024 Korio closed a Series A round led by BIP Ventures with participation from Excelerate Health Ventures, Boston Millennia Partners and other strategic investors, earmarked for global expansion and its client services and support organization. During 2025 the company added Matt Bolinski as SVP, Finance and Arvita Tripati as Vice President, Product & Compliance, and continued publishing RTSM articles, webinars and case studies.